mResvia’s prescribing information indicates that the vaccine was 78.7% effective at preventing RSV that presents with two or more symptoms at 3.7 months of follow-up – a little lower than ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

GSK plc (LSE/NYSE:LON: GSK), a leading pharmaceutical company, announced today that the European Medicines Agency (EMA) has commenced the review process for the use of its adjuvanted recombinant ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

GSK is currently seeking approval for the expanded use of Arexvy in adults aged 18 years and above in the United States and Japan. Year to date, shares of GSK have risen 20.8% against the industry ...

(Alliance News) - GSK PLC on Friday said its respiratory syncytial virus vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand its use in adults 18 ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and olderThe vaccine has been approved for the prevention of RSV-LRTD in individuals 60 years of age and ...

Arexvy is currently approved for the prevention of lower respiratory tract disease (“LRTD”) caused by RSV in all individuals aged 60 years and above, as well as for high-risk individuals aged 50-59 ...

GSK's RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older · Regulatory decision anticipated H1 2026 ...